皓宸医疗科技股份有限公司 2025 年半年度财务报告 皓宸医疗科技股份有限公司 2025 年半年度财务报告 2025 年 08 月 1 皓宸医疗科技股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：皓宸医疗科技股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 111,862,603.68 | 147,693,180.87 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 4,443,525.52 | 9,041,164.44 | | 应收账款 | 27,438,643.26 | 39,169,433.88 | | 应收款项融资 | | | | 预付款项 | 17,400,007.01 | 6,954,032.08 | | 应收保费 | | | | 应 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-019 皓宸医疗科技股份有限公司 1、《皓宸医疗科技股份有限公司第五届监事会第十五次会议决议》。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届监事会第十五次会 议于 2025 年 8 月 17 日以电子邮件的形式发出会议通知，会议于 2025 年 8 月 28 日上午 11:00 以现场结合通讯表决方式召开。本次会议由监事会主席刘月先生主 持，会议应参加表决监事 3 人，实际参加表决监事 3 人。本次会议的内容以及召 集、召开的方式、程序均符合《公司法》和《公司章程》的规定。 与会监事经认真审议，通过如下议案： 一、审议通过《关于 2025 年半年度报告全文及摘要的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票； 表决结果：通过。 经审核，监事会认为董事会编制和审核公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公司《2025 年半年度报告全文》具体内容详见公司指定信息披露网站巨潮 资讯网（www.cni ...

表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 本议案已经公司审计委员会审议并取得了明确同意的意见。 证券代码：002622 证券简称：皓宸医疗 公告编号：2025-018 皓宸医疗科技股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十五次会 议于 2025 年 8 月 28 日上午 10:00 以现场结合通讯表决方式召开。召开本次会议 的通知已于 2025 年 8 月 17 日以电话、电子邮件等方式通知了各位董事。本次会 议由董事长陆璐女士主持，会议应参加表决董事 7 名，实际参加表决董事 7 名。 此次会议的召集、召开与表决程序符合《中华人民共和国公司法》和《公司章程》 及相关法律、法规的规定，合法有效。 与会董事经认真审议，通过如下议案： 一、审议通过《关于 2025 年半年度报告全文及摘要的议案》 1、《皓宸医疗科技股份有限公司第五届董事会第十五次会议决议》。 特此公告。 皓宸医疗科技股份有限公司董事会 二〇二五年八月二十八 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥313,635,948.22, a decrease of 17.90% compared to ¥382,010,234.10 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was a loss of ¥23,751,065.12, representing a significant decline of 4,391.18% from a profit of ¥553,485.18 in the previous year[17]. - The net cash flow from operating activities was negative at ¥27,589,789.01, a decrease of 494.15% compared to ¥6,999,820.53 in the same period last year[17]. - The total assets at the end of the reporting period were ¥1,444,406,852.81, down 3.54% from ¥1,497,483,643.54 at the end of the previous year[17]. - The net assets attributable to shareholders of the listed company decreased by 6.34% to ¥372,781,577.47 from ¥398,035,174.16 at the end of the previous year[17]. - The company reported a basic earnings per share of -¥0.0283, a decline of 4,142.86% compared to ¥0.0007 in the same period last year[17]. - The company reported a net increase in cash and cash equivalents of -¥36,706,921.74, a decrease of 132.00% from -¥15,822,130.24 in the same period last year, largely due to reduced cash inflows from operations[50]. - The company’s investment income decreased by 13.56% to ¥4,349,700.10, reflecting changes in its stake in Fushun Bank[54]. - The company reported a total revenue of 840 million yuan for the current period, with a year-on-year increase of 21%[154]. - The total comprehensive income for the current period was reported at 469 million yuan, highlighting strong overall performance[157]. Business Operations - The core business includes dental medical services and the R&D, production, and sales of permanent magnet switches and high/low voltage switchgear products, forming a dual business operation model[24]. - The dental medical service industry in China is expected to grow significantly, with a market size projected to exceed RMB 200 billion by 2025 and RMB 380 billion by 2030[26]. - 德伦医疗 operates 31 chain clinics covering over 40,000 square meters and has more than 460 dental chairs, making it one of the largest dental service providers in South China[29]. - 永大电气 has established a comprehensive marketing network across over 20 provinces in China, providing integrated pre-sales, sales, and after-sales services[33]. - 永大电气's product line includes various high and low voltage switchgear models, with a focus on smart circuit breakers that meet national smart grid development requirements[34]. - The company has implemented a full-cycle model in production, enhancing product quality and customer satisfaction through comprehensive control from design to after-sales service[36]. - The company has established a strong sales network and is committed to improving customer satisfaction and service quality through a comprehensive quality management system[47]. Risks and Challenges - The company faced significant risks and uncertainties that could impact future performance, as detailed in the risk management section of the report[4]. - The company faces risks related to policy changes in the healthcare sector, particularly in the dental industry, and plans to adjust strategies accordingly[66]. - Increased competition in the dental service market is leading to potential dilution of market share, prompting the company to expand into new regions[68]. - The company has ongoing legal matters related to asset management disputes, with recent court rulings impacting execution procedures[70][71]. - The company has disclosed instances of bank account freezes affecting subsidiaries, which may impact liquidity and operations[73]. Research and Development - Research and development expenses increased significantly by 120.96% to ¥7,966,580.46 from ¥3,605,476.51, indicating a focus on innovation[49]. - Yongda Electric has increased R&D investment to optimize core product performance, focusing on smart and energy-saving upgrades to maintain a technological lead in the industry[38]. - The company has a professional R&D team with 16 senior engineers and 16 intermediate engineers, focusing on continuous innovation in permanent magnet switch products[40]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 48,616[123]. - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of the shares, totaling 200 million shares[123]. - The second-largest shareholder, Shaanxi International Trust Co., Ltd., holds 3.84% of the shares, totaling 32,263,200 shares[123]. Legal and Compliance - The company received a non-standard audit report from Zhonghua Accounting Firm for the fiscal year 2024, highlighting a control dispute involving its largest shareholder, which is currently in litigation[94]. - The company is currently involved in significant litigation, with a total amount of 13,524.55 million yuan related to a case with Zhejiang ZheShang Asset Management Co., Ltd., which is in the execution phase[98]. - The company has not reported any penalties or rectification measures during the reporting period[100]. Future Outlook - The company plans to deepen its market presence in Northeast China, leveraging the 20th anniversary of the Northeast revitalization strategy to expand its customer base and enhance brand influence[38]. - The company is focusing on expanding its market presence and exploring potential mergers and acquisitions[153]. - The company has set a future revenue guidance of 800 billion for the next fiscal year, indicating growth expectations[153]. - The company plans to expand its market presence and invest in new product development to drive future growth[162].

Market Overview - On August 27, the medical services sector declined by 2.14%, with Haitai Biological leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Stock Performance - Notable gainers in the medical services sector included: - Digital Human: Closed at 17.23, up 12.84% with a trading volume of 200,800 shares and a turnover of 355 million [1] - Nanmo Biology: Closed at 62.11, up 8.34% with a trading volume of 41,300 shares and a turnover of 250 million [1] - Dian Diagnostics: Closed at 17.49, up 5.81% with a trading volume of 813,500 shares and a turnover of 1.467 billion [1] - Major decliners included: - Haitai Biological: Closed at 51.28, down 6.87% with a trading volume of 128,800 shares and a turnover of 684 million [2] - Hongbo Pharmaceutical: Closed at 37.93, down 5.79% with a trading volume of 125,600 shares and a turnover of 498 million [2] - Huacheng Medical: Closed at 3.78, down 5.74% with a trading volume of 843,900 shares and a turnover of 328 million [2] Capital Flow - The medical services sector experienced a net outflow of 1.677 billion from institutional investors, while retail investors saw a net inflow of 951 million [2][3] - Key stocks with significant capital flow included: - Jinyu Medical: Net inflow of 120 million from institutional investors, but a net outflow of 79 million from retail investors [3] - Huada Gene: Net inflow of 107 million from institutional investors, with outflows from both retail and speculative investors [3] - Dian Diagnostics: Net inflow of 65.5 million from institutional investors, with outflows from speculative and retail investors [3]

Company Overview - Haochen Medical's stock price closed at 4.01 yuan on August 26, down 0.09 yuan, a decline of 2.20% from the previous trading day [1] - The company operates in the medical services sector, with concepts including medical beauty and smart grid [1] - Haochen Medical has a total market capitalization of 3.368 billion yuan, with circulating market value equal to total market value [1] Stock Performance - On August 26, the stock opened at 4.13 yuan, reached a high of 4.17 yuan, and a low of 4.01 yuan, with a trading volume of 793,867 hands and a transaction amount of 323 million yuan [1] - During the early trading session, the stock experienced a rapid rebound, increasing over 2% within 5 minutes, with a price of 4.13 yuan at 9:35 AM and a transaction amount of 34.93 million yuan [1] Capital Flow - On August 26, there was a net outflow of 2.1781 million yuan from the main funds, accounting for 0.06% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 204.419 million yuan, representing 6.07% of the circulating market value [1]

Group 1 - The stock of Haocen Medical (002622) closed at 4.21 yuan on August 22, 2025, with a 9.92% increase, reaching the daily limit [1][2] - The trading volume for Haocen Medical on the same day was 1.4424 million hands, with a total transaction amount of 585 million yuan [1][2] - The closing order funds amounted to 73.0896 million yuan, representing 2.07% of its circulating market value [1][2] Group 2 - At 13:33, the stock reached its daily limit and closed at 4.21 yuan without being opened again [2] - The net inflow of main funds was 116 million yuan, while retail funds showed a net outflow of 33.2009 million yuan [2] - The net outflow of speculative funds was 82.7291 million yuan [2]

Market Performance - On August 22, the medical services sector rose by 1.29%, with Berry Genomics leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Top Gainers in Medical Services - Berry Genomics (000710) closed at 15.79, up 10.03% with a trading volume of 749,900 shares and a turnover of 1.153 billion yuan [1] - Haochen Medical (002622) closed at 4.21, up 9.92% with a trading volume of 1.4424 million shares and a turnover of 585 million yuan [1] - Golden Domain Medical (603882) closed at 11, up 4.02% with a trading volume of 148,600 shares and a turnover of 461 million yuan [1] Top Losers in Medical Services - Boji Pharmaceutical (300404) closed at 11.37, down 5.09% with a trading volume of 490,800 shares and a turnover of 557 million yuan [2] - ST Shenghua (000504) closed at 9.79, down 3.83% with a trading volume of 85,800 shares and a turnover of 84.73 million yuan [2] - Chengda Pharmaceutical (301201) closed at 30.34, down 3.38% with a trading volume of 104,000 shares and a turnover of 320 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 153 million yuan from institutional investors, while retail investors saw a net inflow of 246 million yuan [2][3] - Berry Genomics had a net inflow of 468 million yuan from institutional investors, but a net outflow of 214 million yuan from speculative funds [3] - Haochen Medical saw a net inflow of 116 million yuan from institutional investors, with a net outflow of 82.73 million yuan from speculative funds [3]

Group 1 - The core viewpoint of the news is that Haocen Medical has experienced a significant stock price increase, reaching a limit up of 9.92% on August 22, with a trading price of 4.21 yuan per share and a total market capitalization of 3.536 billion yuan [1] - Haocen Medical is primarily engaged in oral medical services and industrial manufacturing, with a focus on the research and innovation of permanent magnet switch products [1] - The company was listed on the Shenzhen Stock Exchange in 2011 and acquired a controlling stake in Guangdong Delun Medical Group in 2021 [1] Group 2 - As of March 31, Haocen Medical had 54,000 shareholders, with an average of 15,500 circulating shares per shareholder [2] - For the first quarter of 2025, Haocen Medical reported operating revenue of 143 million yuan, a year-on-year decrease of 12.58%, and a net profit attributable to shareholders of -12.2146 million yuan, a year-on-year decrease of 167.13% [2]

Core Insights - The stock price of Haocen Medical reached 3.96 yuan as of August 20, 2025, marking an increase of 0.36 yuan from the previous trading day [1] - The company operates in the medical services sector, with business activities in medical beauty and smart grid [1] - Haocen Medical has a total market capitalization of 3.326 billion yuan, with circulating market value equal to total market value [1] Financial Performance - On August 20, 2025, the opening price was 3.64 yuan, with a high of 3.96 yuan and a low of 3.63 yuan [1] - The trading volume was 826,976 hands, with a total transaction amount of 322 million yuan [1] - The net inflow of main funds on August 20 was 114.32 million yuan, accounting for 3.44% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow reached 170.64 million yuan, representing 5.13% [1] - In the context of an overall net outflow of 8.096 billion yuan in the pharmaceutical and biotechnology industry, Haocen Medical ranked sixth in terms of net inflow within the sector [1]